<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Scand J Gastroenterol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Scand. J. Gastroenterol</journal-id>
      <journal-id journal-id-type="archive">IGAS</journal-id>
      <journal-id journal-id-type="publisher-id">igas20</journal-id>
      <journal-title-group>
        <journal-title>Scandinavian Journal of Gastroenterology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0036-5521</issn>
      <issn pub-type="epub">1502-7708</issn>
      <publisher>
        <publisher-name>Taylor &amp; Francis</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26728165</article-id>
      <article-id pub-id-type="pmc">4819824</article-id>
      <article-id pub-id-type="doi">10.3109/00365521.2015.1124286</article-id>
      <article-id pub-id-type="publisher-id">1124286</article-id>
      <article-categories>
        <subj-group subj-group-type="article-type">
          <subject>Review</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hepatoid adenocarcinoma of the stomach &#x2013; proper identification and treatment remain a challenge</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>S&#xF8;reide</surname>
            <given-names>Jon Arne</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref>
          <xref ref-type="aff" rid="AF0002">
<sup>b</sup>
</xref>
          <xref ref-type="corresp" rid="AN0001">
<sup>*</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Greve</surname>
            <given-names>Ole Jacob</given-names>
          </name>
          <xref ref-type="aff" rid="AF0003">
<sup>c</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gudlaugsson</surname>
            <given-names>Einar</given-names>
          </name>
          <xref ref-type="aff" rid="AF0004">
<sup>d</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>St&#xF8;rset</surname>
            <given-names>Svein</given-names>
          </name>
          <xref ref-type="aff" rid="AF0005">
<sup>e</sup>
</xref>
        </contrib>
        <aff id="AF0001"><label><sup>a</sup></label><institution><named-content content-type="department">Department of Gastrointestinal Surgery</named-content>, <named-content content-type="institution-name">Stavanger University Hospital</named-content></institution><named-content content-type="city">Stavanger</named-content>,
<country>Norway</country></aff>
        <aff id="AF0002"><label><sup>b</sup></label><institution><named-content content-type="department">Department of Clinical Medicine</named-content>, <named-content content-type="institution-name">University of Bergen</named-content></institution>,
<named-content content-type="city">Bergen</named-content>,
<country>Norway</country></aff>
        <aff id="AF0003"><label><sup>c</sup></label><institution><named-content content-type="department">Department of Radiology</named-content>, <named-content content-type="institution-name">Stavanger University Hospital</named-content></institution>,
<named-content content-type="city">Stavanger</named-content>,
<country>Norway</country></aff>
        <aff id="AF0004"><label><sup>d</sup></label><institution><named-content content-type="department">Department of Pathology</named-content>, <named-content content-type="institution-name">Stavanger University Hospital</named-content></institution>,
<named-content content-type="city">Stavanger</named-content>,
<country>Norway</country></aff>
        <aff id="AF0005"><label><sup>e</sup></label><institution><named-content content-type="department">Department of Gastroenterology</named-content>, <named-content content-type="institution-name">Stavanger University Hospital</named-content></institution>,
<named-content content-type="city">Stavanger</named-content>,
<country>Norway</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="AN0001">CONTACT Jon Arne S&#xF8;reide
<email>jonarne.soreide@uib.no</email><institution><named-content content-type="institution-name">Department of Gastrointestinal Surgery, Stavanger University Hospital</named-content></institution>,
<named-content content-type="postal-code">N-4068</named-content><named-content content-type="city">Stavanger</named-content>,
<country>Norway</country></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>2</day>
        <month>6</month>
        <year>2016</year>
        <!--string-date: June 2016-->
      </pub-date>
      <pub-date pub-type="epub">
        <day>5</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <volume>51</volume>
      <issue>6</issue>
      <fpage seq="3">646</fpage>
      <lpage>653</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>10</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>18</day>
          <month>11</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>11</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 The Author(s). Published by Taylor &amp; Francis.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <copyright-holder>The Author(s).</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/Licenses/by-nc-nd/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/Licenses/by-nc-nd/4.0/">http://creativecommons.org/Licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="igas-51-646.pdf"/>
      <abstract>
        <title>ABSTRACT</title>
        <p>
<bold>Objective</bold> The term hepatoid adenocarcinoma (HAC) of the stomach was introduced three decades ago with the observation of high serum &#x3B1;-fetoprotein (AFP) levels in some gastric adenocarcinoma patients. This very rare gastric cancer patient subgroup is likely frequently misdiagnosed. <bold>Material</bold> Two patients who were recently diagnosed with HAC of the stomach at our institution are presented. We also performed a structured literature search and reviewed pertinent articles to provide knowledge to improve the proper identification, diagnosis and management of patients with gastric HAC. <bold>Results</bold> HAC is a rare subgroup of gastric carcinoma with poor prognosis. Clinical management of this population may be challenging. The scientific literature is largely based on very small patient series or case reports, and the evidence for proper decision making and management is considered weak. <bold>Conclusion</bold> All physicians involved in the diagnosis and treatment of patients with gastric cancer should pay attention to this rare subgroup to improve identification.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>KEYWORDS</title>
        <kwd>Alpha-fetoprotein</kwd>
        <kwd>gastric</kwd>
        <kwd>hepatoid adenocarcinoma</kwd>
        <kwd>prognosis</kwd>
        <kwd>stomach</kwd>
      </kwd-group>
      <counts>
        <page-count count="8"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s0001">
      <title>Introduction</title>
      <p>Although the term hepatoid adenocarcinoma (HAC) of the stomach was introduced in 1985 by Ishikura et&#xA0;al., with the observation of high serum &#x3B1;-fetoprotein (AFP) levels in seven patients with gastric adenocarcinoma,[<xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0002" ref-type="bibr">2</xref>] an AFP-producing gastric tumour was first reported by Bourreille et&#xA0;al.[<xref rid="CIT0003" ref-type="bibr">3</xref>] in 1970. HAC may also originate from other gastrointestinal localisations,[<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0005" ref-type="bibr">5</xref>] including the pancreas.[<xref rid="CIT0006" ref-type="bibr">6</xref>,<xref rid="CIT0007" ref-type="bibr">7</xref>] Moreover, this extrahepatic hepatoid cancer type has also been diagnosed in the ovary,[<xref rid="CIT0008" ref-type="bibr">8</xref>] uterus,[<xref rid="CIT0009" ref-type="bibr">9</xref>] lungs,[<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0011" ref-type="bibr">11</xref>] and several other organs.[<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0012" ref-type="bibr">12</xref>] The scientific literature, however, is mostly based on case reports or very small patient series.[<xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0013" ref-type="bibr">13&#x2013;17</xref>]</p>
      <p>Although previous reports have suggested that the incidence of gastric HAC is between 0.38% and 0.78%, [<xref rid="CIT0015" ref-type="bibr">15</xref>,<xref rid="CIT0018" ref-type="bibr">18</xref>] recent reports from Korea [<xref rid="CIT0014" ref-type="bibr">14</xref>] and China [<xref rid="CIT0019" ref-type="bibr">19</xref>] have provided figures of 0.17% and 0.36%, respectively. HAC is considered an aggressive type of gastric adenocarcinoma with a detrimental prognosis.[<xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0019" ref-type="bibr">19&#x2013;22</xref>] Thus, challenges remain both with regard to the appropriate identification and diagnosis of this rare entity and concerning effective treatments to improve this unfavourable prognosis.</p>
      <p>Based on a review of the available literature and the presentation of two patients who were recently treated at our institution, some relevant clinical aspects are addressed to bring to the attention of both involved clinicians (i.e. gastroenterologists, gastroenterologic surgeons, and oncologists) and pathologists and radiologists: the importance of the correct subclassification of gastric cancer and a better understanding of the characteristics of each subtype to improve early diagnosis and enable appropriate treatment.[<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>]</p>
    </sec>
    <sec id="s0002">
      <title>Material and methods</title>
      <sec id="s0003">
        <title>Literature search</title>
        <p>We searched the PubMed and Ovid Medline databases for articles published between January 2005 and June 2015 using combinations of the terms &#x2018;hepatoid adenocarcinoma&#x2019;, &#x2018;stomach&#x2019;, &#x2018;gastric&#x2019;, &#x2018;gastric cancer&#x2019;, &#x2018;adenocarcinoma&#x2019;, &#x2018;alpha-fetoprotein&#x2019;, &#x2018;treatment&#x2019;, &#x2018;prognosis&#x2019;, and &#x2018;surgery&#x2019;. Earlier seminal and highly regarded publications were considered. References were selected based on the information provided, with an emphasis on patient series and reports that expanded diagnostic tools, improved identification or were found to substantiate fundamental knowledge concerning this condition.</p>
      </sec>
      <sec id="s0004">
        <title>Patients</title>
        <sec id="s0005">
          <title>Case report #1</title>
          <p>An otherwise healthy male (49 years of age), with a two-year history of increasing fatigue, epigastric discomfort, nausea, anaemia, and slightly increasing serum &#x3B1;-fetoprotein (AFP) levels for the last 12 months, was extensively examined over the past year at other hospitals by gastroscopy, coloscopy, liver imaging, including magnetic resonance (MR) imaging, and positron emission tomography&#x2013;computer tomography (PET-CT) without any significant findings.</p>
          <p>Due to anaemia and vague epigastric pains, he was then referred to our hospital where a repeat gastroscopy revealed a large and soft tumour in the proximal part of the stomach (<xref rid="F0001" ref-type="fig">Figure 1</xref>). Serum AFP levels were extremely elevated at 21,045&#xA0;kU/L (normal,&#x2009;&#x2009;&lt;&#x2009;60&#xA0;kU/L) (<xref rid="F0002" ref-type="fig">Figure 2</xref>). Except for a slightly elevated serum chromogranin A (CgA) value of 8.8&#xA0;nmol/L (normal&#x2009;&#x2009;&lt;&#x2009;6.0&#xA0;nmol/L), other tumour markers, including carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA 19-9), were completely normal. Abdominal computer tomography (CT) revealed a large gastric tumour (size: 63&#x2009;&#xD7;&#x2009;77&#x2009;&#xD7;&#x2009;86&#xA0;mm) with a suspicious tumour infiltration of the diaphragm, left liver, and spleen (<xref rid="F0003" ref-type="fig">Figure 3</xref>), but without distant metastases. Histology of the endoscopic biopsy revealed a pattern consistent with gastric adenocarcinoma of the hepatoid subtype (<xref rid="F0004" ref-type="fig">Figure 4</xref>). Upon extended immunohistochemical examination (IHC), strong AFP staining was observed (<xref rid="F0004" ref-type="fig">Figure 4</xref>), but there was no staining of synaptophysin, chromogranin A (CgA), CD 56, or HER2.
<fig id="F0001" orientation="portrait" position="float"><label>Figure 1. </label><caption><p>Pt #1: Male 48 years of age. Endoscopic view of the gastric tumour located in the fundus.</p></caption><graphic xlink:href="igas_a_1124286_f0001_c"/></fig>
<fig id="F0002" orientation="portrait" position="float"><label>Figure 2. </label><caption><p>Time trends of the AFP levels in Pt #1 during the trajectory of his disease.</p></caption><graphic xlink:href="igas_a_1124286_f0002_c"/></fig>
<fig id="F0003" orientation="portrait" position="float"><label>Figure 3. </label><caption><p>Pt #1: Coronal multi detector computer tomography(MDCT) shows the gastric tumour (T) in the left hypochondrium with infiltration of the left hemidiaphragma (stapled arrow) and the greater curvature (arrow) of the stomach.</p></caption><graphic xlink:href="igas_a_1124286_f0003_b"/></fig>
<fig id="F0004" orientation="portrait" position="float"><label>Figure 4. </label><caption><p>(A) Histopathology of hepatoid carcinoma in the gastric mucosal primary lesion The tumour comprised a mixture of pseudoglandular and hepatoid components. Note the normal glandular structure <italic>(arrows</italic>) (haematoxylin and eosin staining; original magnification,&#x2009;&#xD7;400). (B) Immunohistochemical staining showing intracytoplasmic positivity for AFP (dark brown). Note the non-staining normal glandular structure (arrows) (original magnification, x400).</p></caption><graphic xlink:href="igas_a_1124286_f0004_c"/></fig>
</p>
          <p>The patient consented to surgical treatment, which included a total gastrectomy with a wedge resection of the liver and a distal pancreas resection including a splenectomy. In addition, a partial resection of the left diaphragm and a limited resection of the inferior lobe of the lung were performed. The tumour diameter was 80&#xA0;mm, with minimal microscopic infiltration into the liver, diaphragm, and lung, but without evidence of infiltration into the spleen or pancreas. Specimen margins were microscopically tumour free (R0 resection). The tumour was classified (WHO 2010) as pT4bN1M0. Additional IHC of the resected tumour did not show any staining for CD117 (c-kit), and no epidermal growth factor receptor (EGFR) mutation was found with a molecular genetic test.</p>
          <p>The post-operative course was complicated by small bowel obstruction that prompted a re-laparotomy on the eighth post-operative day, with a re-suture (additionally enforced by biological mesh) of the partly disrupted left diaphragm suture line, which had caused an obstruction of a short wedged-in segment of the small bowel. Thereafter, no other specific post-operative surgical complications were encountered, but the patient recovered very slowly after being discharged from the hospital, suffering subjectively from extensive fatigue, which he had also experienced over the last 6 to 9 months pre-operatively, and regaining a normal diet was a challenge. Adjuvant chemotherapy was considered, but due to the patient&#x2019;s impaired clinical condition (ECOG 3) and his own preference, adjuvant treatment was not offered.</p>
          <p>At follow-up 3 months after surgery, lung CT revealed small nodules in the upper left lobe, and abdominal CT demonstrated a metastatic liver lesion of 23&#xA0;mm in diameter, located in the right hemiliver far away from the wedge resection line. Although his general physical status had improved slightly, he was hardly fit for any palliative chemotherapy, which he also refused. The patient died 9 months after surgery for a confirmed hepatoid adenocarcinoma of the stomach.</p>
        </sec>
        <sec id="s0006">
          <title>Case report #2</title>
          <p>An 81-year-old female with weight loss for two months, was admitted with haematemesis. Gastroscopy revealed a large suspicious tumour of the distal stomach. Further work-up including a CT confirmed a large and diffuse gastric tumour, with tumour growth into the surrounding tissues and enlarged mesenteric lymph nodes (LN) in addition to enlarged LN of the lesser curve (<xref rid="F0005" ref-type="fig">Figure 5</xref>). No liver or lung metastases were observed. Tumour markers, including CEA and CA-125, were normal. A significantly elevated serum AFP value of 14,414&#xA0;kU/L (normal,&#x2009;&lt;&#x2009;60&#xA0;kU/L) was encountered. Histology concluded primarily with an adenocarcinoma of the stomach. Based on the increased AFP levels, additional IHC examination of the gastric biopsy was done. A strong staining for AFP was shown, but in addition a few scattered cells (&lt;5%) stained positive both for synaptophysin and for chromogranin A(CgA). This pattern, however, did not allow for the diagnosis of a neuroendocrine tumour. Thus, morphologically the diagnosis of a gastric HAC was made.
<fig id="F0005" orientation="portrait" position="float"><label>Figure 5. </label><caption><p>Pt # 2: Female 81 years of age. (A) Axial MDCT at the time of diagnosis showing <underline>the</underline> gastric tumour (T) located in the antrum, with lymph nodes (LN) at the lesser curvature. (B) Five months after primary diagnosis: disease progression with liver metastasis (<italic>M</italic>), tumour and lymph node growth (<italic>T</italic>) along the lesser curvature, ascites (<italic>A</italic>) and thrombus in portal veins (white arrow).</p></caption><graphic xlink:href="igas_a_1124286_f0005_b"/></fig>
</p>
          <p>Due to the locally advanced tumour and the general health condition of the patient (ECOG 3; ASA 4) as well as her own strong preferences, tumour-directed therapy (i.e. surgery or systemic chemotherapy) was not employed. During the course of the disease, moderate signs of delayed gastric emptying were encountered, and a follow-up CT with findings of a significant tumour growth was performed 6 months after the primary diagnoses. In addition, serum AFP levels of 166,000&#xA0;kU/L were found, which was a 10-fold increase over the 6 months since the time of diagnosis. After a few short hospital admissions for transfusions and supportive care, the patient eventually died 7 months after the diagnosis of a gastric HAC was made.</p>
        </sec>
      </sec>
    </sec>
    <sec id="s0007">
      <title>Results</title>
      <p>The frequency of HAC is extremely low, and the scientific literature comprises mostly case reports or very small patient series. Su et&#xA0;al. reviewed the literature on hepatoid adenocarcinoma between 2001 and 2011 and recently presented a summary on 217 patients, including 182 (83.9%) patients with hepatoid adenocarcinoma located in the stomach.[<xref rid="CIT0004" ref-type="bibr">4</xref>] To add data obtained in more recent years, we have collected pertinent information from recent publications that included a minimum of 10 patients,[<xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0019" ref-type="bibr">19</xref>,<xref rid="CIT0020" ref-type="bibr">20</xref>,<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0025" ref-type="bibr">25</xref>] and relevant information is presented in <xref rid="t0001" ref-type="table">Table 1</xref>. In their review of 26 patients, Baek et&#xA0;al.[<xref rid="CIT0014" ref-type="bibr">14</xref>] observed the predominance of males, the presence of local advanced or metastatic disease in half of the patients at the time of diagnosis, and a Bormann type-III cancer [<xref rid="CIT0026" ref-type="bibr">26</xref>] most frequently found with gastroscopy. A tumour located at the distal area of the stomach (i.e. antrum) was commonly encountered. Similar clinical patterns were in essence reported by two studies from China, one earlier [<xref rid="CIT0015" ref-type="bibr">15</xref>] and one more recent,[<xref rid="CIT0026" ref-type="bibr">26</xref>] with 31 and 20 patients, respectively. Of note is the detrimental prognosis, with an overall survival of less than a year in a large proportion of the patients. Based on the available heterogeneous and limited literature comprising case reports, reliable figures for the true incidence, clinical characteristics, and treatment outcomes are not easily provided.
<table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1. </label><caption><p>Patient characteristics and outcomes presented in five recent series.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th>Author</th><th>Study typeTime periodCountry</th><th>No. of patientsGenderAge, range (years)</th><th>Stage</th><th>ElevatedSerum AFP</th><th>Endoscopy</th><th>Therapy</th><th>Survival,Median (range) Months</th></tr></thead><tbody valign="top"><tr><td>Lin et&#xA0;al.(2015)</td><td>Institution series2001&#x2013;2010Taiwan</td><td>10Male 60%Median 65.5</td><td>Lymph node metastasis 70%Distant (liver) metastasis 50%</td><td>In 7 of 8 pts (88%)Median 359.2&#xA0;ng/mL range, 4.3&#x2013;6,335.6 ng/mL)</td><td>BorrmannType III 60%</td><td>Surgery in 5 patients (50%) without metastasis &#x2013; adjuvant chemo therapy in 4 of these</td><td>OS 7.2 (0.7&#x2013;131.8)20% 5-year survival</td></tr><tr><td>Xie et&#xA0;al.(2015)</td><td>Institution series1999&#x2013;2014China</td><td>19Male 85%Median 61(41&#x2013;80)</td><td>&#x2265;&#x2009;pT3 84.2%pN+&#x2009;70.6%Stage IV 15.8%</td><td>In 10/12 patients with information(range 2.0&#x2013;4375&#xA0;ng/mL)</td><td>Localisation:Cardia 42.1%Body 36.8%Antrum 21.1%</td><td>Surgery for cure in 85%. Adjuvant chemotherapy offered in 12/16 (75%) resected patients.</td><td>OS 12.0DFS 7.0</td></tr><tr><td>Yang et&#xA0;al.(2014)</td><td>Institution series2005&#x2013;2012China</td><td>31Male 68%Mean 51.2(32&#x2013;87)</td><td>Stage I 22.6%Stage II 19.4%Stage III 32.3%Stage IV 25.7%</td><td>87.1% of patients37&#x2013;6400&#xA0;ng/mL</td><td>BorrmannType I 48%Type II 26%Type III 23%Type IV 3%</td><td>Details not available</td><td>OS 631.6% 3-year survival</td></tr><tr><td>Baek et&#xA0;al.(2011)</td><td>Institution series1996&#x2013;2008Korea</td><td>26Male 85%Median 63</td><td>Stage IB 12%Stage II 23%Stage III 27%Stage IV 39%</td><td>In 7 of 11 patients (64%)Median 208&#xA0;ng/mL (range 5&#x2013;4,750,000&#xA0;ng/mL)</td><td>BorrmannType I 9%Type II 22%Type III 48%Type IV 4%EGC<xref rid="TF1" ref-type="table-fn">*</xref> 17%</td><td>Gastrectomy with curative intent in 18 patients (69%). Adjuvant chemotherapy offered in 9 of these patients.</td><td>17 months RFS after gastrectomy. OS 28 months in Stages I&#x2013;III and 8 months in Stage IV. OS was 8 months in patients who received palliative chemotherapy.</td></tr><tr><td>Zhang et&#xA0;al.(2011)</td><td>Institution series1998&#x2013;2009China</td><td>20Males 80%Median 60(40&#x2013;81)</td><td>Stage II 20%Stage III 40%Stage IV 40%</td><td>Reliable information not available</td><td>BorrmannType II 35%Type III 35%ProtrudetType 15%Unspecified 15%</td><td>One gastrectomy, 13 subtotal resections, and 5 palliative resections. 8 patients (40%) received post-op adjuvant chemotherapy.No surgery in one patient</td><td>Median OS 12 months, with a 3-year survival rate of 20%, and 27.5% for those surgically treated.</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>*EGC: early gastric cancer; OS: overall survival; RFS/DFS: relapse-free survival/disease-free survival.</p></fn></table-wrap-foot></table-wrap>
</p>
    </sec>
    <sec id="s0008">
      <title>Discussion</title>
      <p>A proper identification of patients with gastric HAC remains a challenge. Reliable clinical patterns and clues are lacking.</p>
      <p>Imaging does not provide features specific for gastric HAC. Ren et&#xA0;al.[<xref rid="CIT0013" ref-type="bibr">13</xref>] reported six cases with extensively thickened gastric walls by heterogeneous contrast enhancement and a polypoid mass identified at CT. These observations are generally supported by others, who also emphasise the common findings of lymphadenopathy and distant metastases in these groups of patients.[<xref rid="CIT0016" ref-type="bibr">16</xref>,<xref rid="CIT0027" ref-type="bibr">27</xref>] Magnetic resonance imaging (MRI) may help provide a more specific diagnosis, as suggested recently.[<xref rid="CIT0028" ref-type="bibr">28</xref>] In contrast to our male patient without any uptake on PET-CT, others have reported positive findings in patients with HAC.[<xref rid="CIT0005" ref-type="bibr">5</xref>,<xref rid="CIT0029" ref-type="bibr">29</xref>]</p>
      <p>Morphologically, hepatoid adenocarcinoma of the stomach is a type of extrahepatic carcinoma with a complex histological picture, including enteroblastic and hepatic differentiation.[<xref rid="CIT0030" ref-type="bibr">30</xref>] However, its similarity to hepatocellular carcinoma (HCC) of the liver is evident. As originally described by Ishikura et&#xA0;al.,[<xref rid="CIT0001" ref-type="bibr">1</xref>] these gastric carcinomas comprise both adenocarcinomatous and hepatocellular differentiations. The adenocarcinomatous and hepatoid areas were often intermingled with each other, and an extensive venous involvement by tumour cells was noted.[<xref rid="CIT0001" ref-type="bibr">1</xref>] Moreover, the tumour cells contain various serum proteins, including AFP, alpha-1 antitrypsin (AAT), alpha-1 antichymotrypsin (ACT), albumin, and prealbumin, in their cytoplasm, which can be shown by positive immunohistochemical staining. Because HAC and HCC cannot be differentiated on the basis of morphology alone, differences in immunehistochemical reaction patterns may enable the correct diagnosis. As shown in several reports, immune staining for CK7, CK8, CK18, CK19, CK20, alpha-fetoprotein (AFP), p-CEA, and HepPar1 revealed that hepatoid areas of both primary and metastatic HAC have a specific immune profile that is distinct to this entity.[<xref rid="CIT0031" ref-type="bibr">31&#x2013;34</xref>] This should help the pathologist once a diagnosis of HAC has been considered.</p>
      <p>AFP is a foetal serum protein produced by foetal and yolk sac cells and by some foetal gastrointestinal cells. After birth, the level of the protein in the serum rapidly decreases. AFP as a tumour marker is not by itself diagnostic, only suggestive. Whereas elevated levels of AFP are mainly associated with the occurrence of a hepatocellular carcinoma (HCC), a number of other tumours including non-seminomatous germ cell tumours and endodermal sinus tumours (i.e. york sac carcinoma) can give rise to increased AFP levels.[<xref rid="CIT0005" ref-type="bibr">5</xref>,<xref rid="CIT0006" ref-type="bibr">6</xref>,<xref rid="CIT0035" ref-type="bibr">35&#x2013;38</xref>] If AFP is measured, the interpretation of a raised AFP level may not be straightforward, which is particularly important in endemic areas with a high incidence of chronic hepatitis B and C and HCC. Although most patients (at least 80%) with gastric HAC will have elevated serum AFP levels, this is not the case in all patients with gastric HAC. [<xref rid="CIT0004" ref-type="bibr">4</xref>] As observed in our male patient and as observed by others, a resection of the tumour causes a decrease in AFP levels, which eventually increases again when distant metastases are evident.</p>
      <p>Thus, hepatoid adenocarcinoma (HAC) is a rare but important specific type of extrahepatic adenocarcinoma that should be distinguished from HCC.[<xref rid="CIT0004" ref-type="bibr">4</xref>] Although the stomach is by far the most prevalent location, other gastrointestinal locations [<xref rid="CIT0039" ref-type="bibr">39&#x2013;41</xref>] and the genitals have been reported.[<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0008" ref-type="bibr">8</xref>,<xref rid="CIT0037" ref-type="bibr">37</xref>]</p>
      <p>The so-called composite or mixed tumour with hepatoid and neuroendocrine differentiation in the same gastric tumour has been reported,[<xref rid="CIT0042" ref-type="bibr">42&#x2013;44</xref>] which has also been encountered in HAC tumours of other locations (i.e. pancreas).[<xref rid="CIT0007" ref-type="bibr">7</xref>,<xref rid="CIT0038" ref-type="bibr">38</xref>] Still, the clinicopathologically importance and understanding of the composition of a gastric HAC and a neuroendocrine cancer remains uncertain.[<xref rid="CIT0043" ref-type="bibr">43</xref>] As also shown in the tumour of our patient #2, a very weak IHC staining (&lt;5% of the cells) for CgA was encountered, although fare too weak to support a diagnosis of a mixture with a HAC and a neuroendocrine tumour in this case.</p>
      <p>We have not been able to find any evidence for a relationship between gastric HAC and known risk factors for developing a common gastric adenocarcinoma, such as <italic>H. pylori</italic> infection or chronic atrophic gastritis. Of note is a reported substantial male predominance,[<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0014" ref-type="bibr">14</xref>] but it remains to be shown if any specific factors can explain this gender difference.</p>
      <p>Recently, Vivekanandarajah et&#xA0;al.[<xref rid="CIT0021" ref-type="bibr">21</xref>] claimed that they were the first to report on a patient with AFP-producing gastric adenocarcinoma without hepatic metastases. Neither of our two patients had liver metastases as demonstrated by imaging at the time of diagnosis, and although advanced disease is common in this particular subgroup of patients with gastric cancer, recent reports have already shown that a proportion of these patients are diagnosed with local disease.[<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0020" ref-type="bibr">20</xref>]</p>
      <p>Although prognosis appears detrimental despite the treatments employed, a number of patients have been surgically treated. Our male patient had a locally advanced disease, and radical surgery with free margins was achieved. Nevertheless, an early recurrence and a short survival were observed, which has also been reported by others.[<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0019" ref-type="bibr">19</xref>,<xref rid="CIT0020" ref-type="bibr">20</xref>] Adjuvant chemotherapy treatments have been employed, but it remains to be shown which drugs or combinations of drugs should be used, and the evidence is weak based on the limited clinical experience.[<xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0019" ref-type="bibr">19</xref>,<xref rid="CIT0045" ref-type="bibr">45</xref>] The same applies for neoadjuvant chemotherapy [<xref rid="CIT0046" ref-type="bibr">46</xref>,<xref rid="CIT0047" ref-type="bibr">47</xref>] and palliative systemic treatments,[<xref rid="CIT0048" ref-type="bibr">48</xref>,<xref rid="CIT0049" ref-type="bibr">49</xref>] which have been offered to a small number of patients.</p>
      <p>As already stated by Ishikura et&#xA0;al.[<xref rid="CIT0001" ref-type="bibr">1</xref>] when they first described this entity in 1986, the observed poor prognosis may be attributed to the observed mixture of adenocarcinomatous foci and hepatoid areas and to the production of AFP and the presence of alpha-1 antitrypsin (AAT) and alpha-1 antichymotrypsin (ACT), which have immunosuppressive and protease-inhibitory properties. The detrimental prognosis and the aggressive biological behaviour of this gastric cancer subtype may also be partly explained by the finding of a high malignant potential (high proliferative activity, weak apoptosis, and rich neovascularisation) in AFP-positive gastric cancers compared with AFP-negative gastric cancers.[<xref rid="CIT0050" ref-type="bibr">50</xref>]</p>
      <p>Likely, a number of gastric cancer patients with the HAC subtype, whether it is AFP-producing or not, are misdiagnosed.[<xref rid="CIT0023" ref-type="bibr">23</xref>] The correct diagnosis of malignancy, a precise classification of the tumour type and an appropriate staging of the disease are all important factors to provide suitable and individualised surgical or oncologic treatment to improve prognosis and patient care. This pathology was first described almost three decades ago,[<xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0002" ref-type="bibr">2</xref>] and since then, a number of reports have been published, mostly in the context of case reports and small patient series. Nevertheless, the community of gastroenterologists, hepatologists, endoscopists, gastrointestinal surgeons, pathologist, radiologists, and oncologists should all bring this disease to their attention to arrive at a correct diagnosis that may enable appropriate treatment to improve patient care and the dismal prognosis of this pathology.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>The valuable and professional assistance with the literature search provided by the hospital research librarian Jannicke Rusnes Lie is highly appreciated.</p>
      <sec id="s0009">
        <title>Disclosure statement</title>
        <p>The authors report no conflict of interest.</p>
      </sec>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="CIT0001">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishikura</surname><given-names>H</given-names></name><name><surname>Kirimoto</surname><given-names>K</given-names></name><name><surname>Shamoto</surname><given-names>M</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid adenocarcinomas of the stomach. An analysis of seven cases.</article-title>
<source>Cancer</source>
<year>1986</year>
<volume>58</volume>
<fpage>119</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="pmid">2423220</pub-id></element-citation>
      </ref>
      <ref id="CIT0002">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishikura</surname><given-names>H</given-names></name><name><surname>Fukasawa</surname><given-names>Y</given-names></name><name><surname>Ogasawara</surname><given-names>K</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report.</article-title>
<source>Cancer</source>
<year>1985</year>
<volume>56</volume>
<fpage>840</fpage>
<lpage>848</lpage>
<pub-id pub-id-type="pmid">2410093</pub-id></element-citation>
      </ref>
      <ref id="CIT0003">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bourreille</surname><given-names>J</given-names></name><name><surname>Metayer</surname><given-names>P</given-names></name><name><surname>Sauger</surname><given-names>F</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Existence of alfa feto protein during gastric-origin secondary cancer of the liver.</article-title>
<source>Presse Med</source>
<year>1970</year>
<volume>78</volume>
<fpage>1277</fpage>
<lpage>1278</lpage>
<pub-id pub-id-type="pmid">5426134</pub-id></element-citation>
      </ref>
      <ref id="CIT0004">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Su</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Wang</surname><given-names>RC</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review.</article-title>
<source>World J Gastroenterol</source>
<year>2013</year>
<volume>19</volume>
<fpage>321</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="pmid">23372352</pub-id></element-citation>
      </ref>
      <ref id="CIT0005">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Bao</surname><given-names>WQ</given-names></name><name><surname>Hua</surname><given-names>FC</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>AFP-producing hepatoid adenocarcinoma of appendix: a case report of 18F-FDG PET/CT.</article-title>
<source>Clin Imaging</source>
<year>2014</year>
<volume>38</volume>
<fpage>526</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="pmid">24721022</pub-id></element-citation>
      </ref>
      <ref id="CIT0006">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marchegiani</surname><given-names>G</given-names></name><name><surname>Gareer</surname><given-names>H</given-names></name><name><surname>Parisi</surname><given-names>A</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Pancreatic hepatoid carcinoma: a review of the literature.</article-title>
<source>Dig Surg</source>
<year>2013</year>
<volume>30</volume>
<fpage>425</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="pmid">24281319</pub-id></element-citation>
      </ref>
      <ref id="CIT0007">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jung</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid carcinoma of the pancreas combined with neuroendocrine carcinoma.</article-title>
<source>Gut Liver</source>
<year>2010</year>
<volume>4</volume>
<fpage>98</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="pmid">20479919</pub-id></element-citation>
      </ref>
      <ref id="CIT0008">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lazaro</surname><given-names>J</given-names></name><name><surname>Rubio</surname><given-names>D</given-names></name><name><surname>Repolles</surname><given-names>M</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid carcinoma of the ovary and management.</article-title>
<source>Acta Obstet Gynecol Scand</source>
<year>2007</year>
<volume>86</volume>
<fpage>498</fpage>
<lpage>499</lpage>
<pub-id pub-id-type="pmid">17486476</pub-id></element-citation>
      </ref>
      <ref id="CIT0009">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>T.</given-names></name></person-group>
<article-title>Hepatoid carcinoma of the uterus that collided with carcinosarcoma.</article-title>
<source>Pathol Int</source>
<year>2003</year>
<volume>53</volume>
<fpage>323</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="pmid">12713569</pub-id></element-citation>
      </ref>
      <ref id="CIT0010">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arnould</surname><given-names>L</given-names></name><name><surname>Drouot</surname><given-names>F</given-names></name><name><surname>Fargeot</surname><given-names>P</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid adenocarcinoma of the lung: report of a case of an unusual alpha-fetoprotein-producing lung tumor.</article-title>
<source>Am J Surg Pathol</source>
<year>1997</year>
<volume>21</volume>
<fpage>1113</fpage>
<lpage>1118</lpage>
<pub-id pub-id-type="pmid">9298890</pub-id></element-citation>
      </ref>
      <ref id="CIT0011">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishikura</surname><given-names>H</given-names></name><name><surname>Kanda</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid adenocarcinoma: a distinctive histological subtype of alpha-fetoprotein-producing lung carcinoma.</article-title>
<source>Virchows Arch a Pathol Anat Histopathol</source>
<year>1990</year>
<volume>417</volume>
<fpage>73</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">1694332</pub-id></element-citation>
      </ref>
      <ref id="CIT0012">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roberts</surname><given-names>CC</given-names></name><name><surname>Colby</surname><given-names>TV</given-names></name><name><surname>Batts</surname><given-names>KP.</given-names></name></person-group>
<article-title>Carcinoma of the stomach with hepatocyte differentiation (hepatoid adenocarcinoma).</article-title>
<source>Mayo Clin Proceed</source>
<year>1997</year>
<volume>72</volume>
<fpage>1154</fpage>
<lpage>1160</lpage>
</element-citation>
      </ref>
      <ref id="CIT0013">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ren</surname><given-names>A</given-names></name><name><surname>Cai</surname><given-names>F</given-names></name><name><surname>Shang</surname><given-names>YN</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Gastric hepatoid adenocarcinoma: a computed tomography report of six cases.</article-title>
<source>World J Gastroenterol</source>
<year>2014</year>
<volume>20</volume>
<fpage>15001</fpage>
<lpage>15006</lpage>
<pub-id pub-id-type="pmid">25356063</pub-id></element-citation>
      </ref>
      <ref id="CIT0014">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baek</surname><given-names>SK</given-names></name><name><surname>Han</surname><given-names>SW</given-names></name><name><surname>Oh</surname><given-names>DY</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer.</article-title>
<source>BMC Gastroenterol</source>
<year>2011</year>
<volume>11</volume>
<fpage>56</fpage>
<pub-id pub-id-type="pmid">21592404</pub-id></element-citation>
      </ref>
      <ref id="CIT0015">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nagai</surname><given-names>E</given-names></name><name><surname>Ueyama</surname><given-names>T</given-names></name><name><surname>Yao</surname><given-names>T</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid adenocarcinoma of the stomach. A clinicopathologic and immunohistochemical analysis.</article-title>
<source>Cancer</source>
<year>1993</year>
<volume>72</volume>
<fpage>1827</fpage>
<lpage>1835</lpage>
<pub-id pub-id-type="pmid">7689918</pub-id></element-citation>
      </ref>
      <ref id="CIT0016">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>MW</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Gastric hepatoid adenocarcinoma: CT findings.</article-title>
<source>Abdom Imaging</source>
<year>2007</year>
<volume>32</volume>
<fpage>293</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="pmid">16967243</pub-id></element-citation>
      </ref>
      <ref id="CIT0017">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giustozzi</surname><given-names>G</given-names></name><name><surname>Goracci</surname><given-names>G</given-names></name><name><surname>Bufalari</surname><given-names>A</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid carcinoma of the stomach: is it still an unusual anatomo-clinical entity? Six cases-report.</article-title>
<source>J Exp Clin Cancer Res</source>
<year>1999</year>
<volume>18</volume>
<fpage>571</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="pmid">10746988</pub-id></element-citation>
      </ref>
      <ref id="CIT0018">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>YB</given-names></name><name><surname>Zhang</surname><given-names>DF</given-names></name><name><surname>Jin</surname><given-names>XL</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Preliminary study on the clinical and pathological relevance of gastric hepatoid adenocarcinoma.</article-title>
<source>J Dig Dis</source>
<year>2007</year>
<volume>8</volume>
<fpage>23</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">17261131</pub-id></element-citation>
      </ref>
      <ref id="CIT0019">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JF</given-names></name><name><surname>Shi</surname><given-names>SS</given-names></name><name><surname>Shao</surname><given-names>YF</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Clinicopathological and prognostic features of hepatoid adenocarcinoma of the stomach.</article-title>
<source>Chin Med J (Engl)</source>
<year>2011</year>
<volume>124</volume>
<fpage>1470</fpage>
<lpage>1476</lpage>
<pub-id pub-id-type="pmid">21740800</pub-id></element-citation>
      </ref>
      <ref id="CIT0020">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Clinicopathological and prognostic characteristics of hepatoid adenocarcinoma of the stomach.</article-title>
<source>Gastroenterol Res Pract</source>
<year>2014</year>
<volume>2014</volume>
<fpage>140587</fpage>
<pub-id pub-id-type="pmid">24669215</pub-id></element-citation>
      </ref>
      <ref id="CIT0021">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vivekanandarajah</surname><given-names>A</given-names></name><name><surname>Atallah</surname><given-names>JP</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name></person-group>
<article-title>Alpha-fetoprotein-producing nonmetastatic gastric adenocarcinoma: a rare entity.</article-title>
<source>J Gastrointest Cancer</source>
<year>2014</year>
<volume>45</volume>
<fpage>225</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="pmid">23595784</pub-id></element-citation>
      </ref>
      <ref id="CIT0022">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ye</surname><given-names>MF</given-names></name><name><surname>Tao</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid adenocarcinoma of the stomach: a report of three cases.</article-title>
<source>World J Gastroenterol</source>
<year>2013</year>
<volume>19</volume>
<fpage>4437</fpage>
<lpage>4442</lpage>
<pub-id pub-id-type="pmid">23885160</pub-id></element-citation>
      </ref>
      <ref id="CIT0023">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid adenocarcinoma of the stomach is a special and easily misdiagnosed or missed diagnosed subtype of gastric cancer with poor prognosis but curative for patients of pN0/1: the experience of a single center.</article-title>
<source>Int J Clin Exp Med</source>
<year>2015</year>
<volume>8</volume>
<fpage>6762</fpage>
<lpage>6772</lpage>
<pub-id pub-id-type="pmid">26221214</pub-id></element-citation>
      </ref>
      <ref id="CIT0024">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>El Hajj</surname><given-names>N</given-names></name><name><surname>Sittler</surname><given-names>S</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Gastric cancer: Classification, histology and application of molecular pathology.</article-title>
<source>J Gastrointest Oncol</source>
<year>2012</year>
<volume>3</volume>
<fpage>251</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="pmid">22943016</pub-id></element-citation>
      </ref>
      <ref id="CIT0025">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Yeh</surname><given-names>HC</given-names></name><name><surname>Hsu</surname><given-names>CM</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Clinicopathologial features of gastric hepatoid adenocarcinoma.</article-title>
<source>Biomed J</source>
<year>2015</year>
<volume>38</volume>
<fpage>65</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="pmid">25163499</pub-id></element-citation>
      </ref>
      <ref id="CIT0026">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer.</article-title>
<source>Oncology</source>
<year>2009</year>
<volume>77</volume>
<fpage>197</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="pmid">19729977</pub-id></element-citation>
      </ref>
      <ref id="CIT0027">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Upadhyaya</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid adenocarcinoma: computed tomographic imaging findings with histopathologic correlation in 6 cases.</article-title>
<source>J Comput Assist Tomogr</source>
<year>2007</year>
<volume>31</volume>
<fpage>846</fpage>
<lpage>852</lpage>
<pub-id pub-id-type="pmid">18043368</pub-id></element-citation>
      </ref>
      <ref id="CIT0028">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Velut</surname><given-names>G</given-names></name><name><surname>Mary</surname><given-names>F</given-names></name><name><surname>Aflalo</surname><given-names>V</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Magnetic resonance imaging diffusion-weighted imaging for diagnosis of a gastric hepatoid adenocarcinoma.</article-title>
<source>Dig Liver Dis</source>
<year>2015</year>
<volume>47</volume>
<fpage>174</fpage>
<pub-id pub-id-type="pmid">25249152</pub-id></element-citation>
      </ref>
      <ref id="CIT0029">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seo</surname><given-names>HJ</given-names></name><name><surname>Chung</surname><given-names>JK</given-names></name><name><surname>Go</surname><given-names>H</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>A hepatoid adenocarcinoma of the stomach evaluated with (18)F-FDG PET/CT: intense (18)F-FDG uptake contrary to the previous report.</article-title>
<source>Clin Nucl Med</source>
<year>2014</year>
<volume>39</volume>
<fpage>442</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="pmid">24152637</pub-id></element-citation>
      </ref>
      <ref id="CIT0030">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Ichikawa</surname><given-names>K</given-names></name><name><surname>Takagaki</surname><given-names>T</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Genetic evolution of alpha fetoprotein producing gastric cancer.</article-title>
<source>J Clin Pathol</source>
<year>2003</year>
<volume>56</volume>
<fpage>942</fpage>
<lpage>949</lpage>
<pub-id pub-id-type="pmid">14645355</pub-id></element-citation>
      </ref>
      <ref id="CIT0031">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Supriatna</surname><given-names>Y</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Uno</surname><given-names>T</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Evidence for hepatocellular differentiation in alpha-fetoprotein-negative gastric adenocarcinoma with hepatoid morphology: a study with in situ hybridisation for albumin mRNA.</article-title>
<source>Pathology</source>
<year>2005</year>
<volume>37</volume>
<fpage>211</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="pmid">16175893</pub-id></element-citation>
      </ref>
      <ref id="CIT0032">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terracciano</surname><given-names>LM</given-names></name><name><surname>Glatz</surname><given-names>K</given-names></name><name><surname>Mhawech</surname><given-names>P</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases.</article-title>
<source>Am J Surg Pathol</source>
<year>2003</year>
<volume>27</volume>
<fpage>1302</fpage>
<lpage>1312</lpage>
<pub-id pub-id-type="pmid">14508391</pub-id></element-citation>
      </ref>
      <ref id="CIT0033">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wee</surname><given-names>A</given-names></name><name><surname>Thamboo</surname><given-names>TP</given-names></name><name><surname>Thomas</surname><given-names>A.</given-names></name></person-group>
<article-title>Alpha-fetoprotein-producing liver carcinomas of primary extrahepatic origin.</article-title>
<source>Acta Cytol</source>
<year>2003</year>
<volume>47</volume>
<fpage>799</fpage>
<lpage>808</lpage>
<pub-id pub-id-type="pmid">14526683</pub-id></element-citation>
      </ref>
      <ref id="CIT0034">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sentani</surname><given-names>K</given-names></name><name><surname>Oue</surname><given-names>N</given-names></name><name><surname>Sakamoto</surname><given-names>N</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach.</article-title>
<source>Mod Pathol</source>
<year>2008</year>
<volume>21</volume>
<fpage>464</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="pmid">18204429</pub-id></element-citation>
      </ref>
      <ref id="CIT0035">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duffy</surname><given-names>MJ.</given-names></name></person-group>
<article-title>Evidence for the clinical use of tumour markers.</article-title>
<source>Ann Clin Biochem</source>
<year>2004</year>
<volume>41</volume>
<fpage>370</fpage>
<lpage>377</lpage>
<pub-id pub-id-type="pmid">15333188</pub-id></element-citation>
      </ref>
      <ref id="CIT0036">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Yoneda</surname><given-names>N</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Alpha-fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.</article-title>
<source>Hum Pathol</source>
<year>2012</year>
<volume>43</volume>
<fpage>1955</fpage>
<lpage>1963</lpage>
<pub-id pub-id-type="pmid">22516245</pub-id></element-citation>
      </ref>
      <ref id="CIT0037">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Samaratunga</surname><given-names>H</given-names></name><name><surname>Samaratunga</surname><given-names>D</given-names></name><name><surname>Dunglison</surname><given-names>N</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Alpha-fetoprotein-producing carcinoma of the renal pelvis exhibiting hepatoid and urothelial differentiation.</article-title>
<source>Anticancer Res</source>
<year>2012</year>
<volume>32</volume>
<fpage>4987</fpage>
<lpage>4991</lpage>
<pub-id pub-id-type="pmid">23155269</pub-id></element-citation>
      </ref>
      <ref id="CIT0038">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Yong</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Pure alpha-fetoprotein-producing neuroendocrine carcinoma of the pancreas: a case report.</article-title>
<source>BMC Gastroenterol</source>
<year>2015</year>
<volume>15</volume>
<fpage>16</fpage>
<pub-id pub-id-type="pmid">25886790</pub-id></element-citation>
      </ref>
      <ref id="CIT0039">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rassidakis</surname><given-names>GZ</given-names></name><name><surname>Delladetsima</surname><given-names>JK</given-names></name><name><surname>Letsos</surname><given-names>SP</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid adenocarcinoma of the stomach with extensive neuroendocrine differentiation and a coexisting carcinoid tumour.</article-title>
<source>Histopathology</source>
<year>1998</year>
<volume>33</volume>
<fpage>8</fpage>
<lpage>186</lpage>
</element-citation>
      </ref>
      <ref id="CIT0040">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lam</surname><given-names>K</given-names></name><name><surname>Lo</surname><given-names>C</given-names></name><name><surname>Wat</surname><given-names>M</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Malignant insulinoma with hepatoid differentiation: a unique case with alpha-fetoprotein production.</article-title>
<source>Endocr Pathol</source>
<year>2001</year>
<volume>12</volume>
<fpage>351</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="pmid">11740056</pub-id></element-citation>
      </ref>
      <ref id="CIT0041">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Metzgeroth</surname><given-names>G</given-names></name><name><surname>Strobel</surname><given-names>P</given-names></name><name><surname>Baumbusch</surname><given-names>T</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Hepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity.</article-title>
<source>Onkologie</source>
<year>2010</year>
<volume>33</volume>
<fpage>263</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="pmid">20502062</pub-id></element-citation>
      </ref>
      <ref id="CIT0042">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wincewicz</surname><given-names>A</given-names></name><name><surname>Kowalik</surname><given-names>A</given-names></name><name><surname>Zieba</surname><given-names>S</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Alpha-fetoprotein-producing hepatoid gastric adenocarcinoma with osteoclast-like giant cells and neuroendocrine differentiation: a case study with molecular profiling.</article-title>
<source>Int J Surg Pathol</source>
<year>2015</year>
<volume>23</volume>
<fpage>537</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="pmid">26009570</pub-id></element-citation>
      </ref>
      <ref id="CIT0043">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Koide</surname><given-names>N</given-names></name><name><surname>Kitazawa</surname><given-names>M</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Gastric composite tumor of alpha fetoprotein-producing carcinoma/hepatoid adenocarcinoma and endocrine carcinoma with reference to cellular phenotypes.</article-title>
<source>Pathol Res Int</source>
<year>2012</year>
<volume>2012</volume>
<fpage>201375</fpage>
</element-citation>
      </ref>
      <ref id="CIT0044">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>T</given-names></name><name><surname>Ogasahara</surname><given-names>K</given-names></name><name><surname>Fujiki</surname><given-names>M</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Primary coexistent neuroendocrine carcinoma, hepatoid adenocarcinoma, and tubular adenocarcinoma of the stomach with focal trophoblastic differentiation in metastatic lymph nodes.</article-title>
<source>J Gastroenterol</source>
<year>2003</year>
<volume>38</volume>
<fpage>608</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="pmid">12858843</pub-id></element-citation>
      </ref>
      <ref id="CIT0045">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Velut</surname><given-names>G</given-names></name><name><surname>Mary</surname><given-names>F</given-names></name><name><surname>Wind</surname><given-names>P</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Adjuvant chemotherapy by FOLFOX for gastric hepatoid adenocarcinoma.</article-title>
<source>Dig Liver Dis</source>
<year>2014</year>
<volume>46</volume>
<fpage>1135</fpage>
<lpage>1136</lpage>
<pub-id pub-id-type="pmid">25179158</pub-id></element-citation>
      </ref>
      <ref id="CIT0046">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kochi</surname><given-names>M</given-names></name><name><surname>Fujii</surname><given-names>M</given-names></name><name><surname>Kaiga</surname><given-names>T</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>FLEP chemotherapy for alpha-fetoprotein-producing gastric cancer.</article-title>
<source>Oncology</source>
<year>2004</year>
<volume>66</volume>
<fpage>445</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="pmid">15452373</pub-id></element-citation>
      </ref>
      <ref id="CIT0047">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakao</surname><given-names>S</given-names></name><name><surname>Nakata</surname><given-names>B</given-names></name><name><surname>Tendo</surname><given-names>M</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Salvage surgery after chemotherapy with S-1 plus cisplatin for alpha-fetoprotein-producing gastric cancer with a portal vein tumor thrombus: a case report.</article-title>
<source>BMC Surg</source>
<year>2015</year>
<volume>15</volume>
<fpage>5</fpage>
<pub-id pub-id-type="pmid">25591731</pub-id></element-citation>
      </ref>
      <ref id="CIT0048">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takeyama</surname><given-names>H</given-names></name><name><surname>Sawai</surname><given-names>H</given-names></name><name><surname>Wakasugi</surname><given-names>T</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases.</article-title>
<source>World J Surg Oncol</source>
<year>2007</year>
<volume>5</volume>
<fpage>79</fpage>
<pub-id pub-id-type="pmid">17634124</pub-id></element-citation>
      </ref>
      <ref id="CIT0049">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shimada</surname><given-names>S</given-names></name><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Marutsuka</surname><given-names>T</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Irinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases.</article-title>
<source>Surg Today</source>
<year>2002</year>
<volume>32</volume>
<fpage>1075</fpage>
<lpage>1080</lpage>
<pub-id pub-id-type="pmid">12541026</pub-id></element-citation>
      </ref>
      <ref id="CIT0050">
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koide</surname><given-names>N</given-names></name><name><surname>Nishio</surname><given-names>A</given-names></name><name><surname>Igarashi</surname><given-names>J</given-names></name><etal>et&#xA0;al</etal></person-group>
<article-title>Alpha-fetoprotein-producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis.</article-title>
<source>Am J Gastroenterol</source>
<year>1999</year>
<volume>94</volume>
<fpage>1658</fpage>
<lpage>1663</lpage>
<pub-id pub-id-type="pmid">10364040</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
